1032507-45-1

Basic information

• Product Name: 4-Bromo-3-chlorobenzenesulfonamide
• Synonyms: 4-Bromo-3-chlorobenzenesulfonamide
• CAS NO: 1032507-45-1
• Molecular Formula: C₆H₅BrClNO₂S
• Molecular Weight: 270.5314
• Mol File: 1032507-45-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Bromo-3-chlorobenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-3-chlorobenzenesulfonamide(1032507-45-1)
• EPA Substance Registry System: 4-Bromo-3-chlorobenzenesulfonamide(1032507-45-1)

Safety Data

• Hazardous Substances Data: 1032507-45-1(Hazardous Substances Data)

Usage

Uses

4-Bromo-3-chlorobenzenesulfonamide behaves as a disruptor of the Glucokinase-Glucokinase regulatory protein interaction. For the 2-chloro species, see B677990.

Upstream product

• 874801-46-4 4-bromo-3-chlorobenzene-1-sulfonyl chloride 

Downstream Products

• 1338326-28-5 4'-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)-2-chlorobiphenyl-4-sulfonamide 

Relevant articles and documents

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration

Currently, the therapeutic options for treatment of liver failure are very limited. As mitogen-activated protein kinase kinase 4 (MKK4) has recently been identified by in vivo RNAi experiments to be a major regulator in hepatocyte regeneration, we pursued the development of a small molecule targeting this protein kinase. Starting from the approved BRAFV600E inhibitor vemurafenib (8), that showed a high off-target affinity to MKK4 in an initial screening, we followed a scaffold-hopping approach, changing the core heterocycle from 1H-pyrrolo[2,3-b]pyridine to 1H-pyrazolo[2,3-b]pyridine (10). Affinity to MKK4 could be conserved while the selectivity against off-target protein kinases was slightly improved. Further modifications led to 58 and 59 showing high affinity to MKK4 in the low nanomolar range and excellent selectivity profile from mandatory multiparameter-optimization for the essential anti-targets (MKK7, JNK1) and off-targets (BRAF, MAP4K5, ZAK) in the MKK4 pathway. Herein we report the first selective MKK4 inhibitors in this class.

PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.